Articles related to PARKINSON'S DISEASE (PD)

Manifest Technologies is spearheading the use of AI in developing targeted treatments for CNS disorders, aiming to refine patient selection in clinical trials and enhance therapeutic outcomes.

This study sheds light on lixisenatide’s potential in Parkinson’s disease, showing a notable slowing of motor disability progression, although accompanied by gastrointestinal side effects, underlining the importance of further research to validate these findings.

Recent research underscores a notable correlation between high pesticide and herbicide exposure and increased Parkinson’s disease risk, emphasizing the need for healthcare professionals to consider environmental factors in their assessment and patient education strategies.

The latest findings on the association between pesticide exposure and Parkinson’s disease risk offer new insights into environmental factors contributing to the growing prevalence of this neurological disorder.

This study unveils a blood-based biomarker test capable of identifying individuals at risk of Parkinson’s Disease and related dementias with remarkable precision, promising a new era in the proactive management of neurodegenerative disorders.

In a landmark effort, seven molecules targeting the genetic roots of familial Parkinson’s disease were identified, showcasing the power of AI and open science in advancing treatment options. This collaborative achievement offers new avenues for understanding and potentially treating this challenging neurological disorder.